Amgen publishes Q3 2026 earnings presentation
Bitget2026/11/03 21:27- Amgen’s third-quarter 2026 revenue rose 8% year over year to $10.4 billion.
- Non-GAAP earnings per share increased 14% to $6.45; non-GAAP operating margin reached 47%.
- Non-GAAP research and development spending rose 11% to $2.1 billion.
- Rare disease sales grew 37%, innovative oncology sales increased 21%, and biosimilar sales rose 26%.
- Seventeen products posted double-digit sales growth; 17 products were annualizing at $1 billion or more based on quarterly sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq
Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.
Crypto prices
More
